Parliamentary Exchange on Antimicrobial Resistance – Answered 5th April 2017

Kevin Hollinrake MP for Thirsk and Malton asked the Secretary of State for Health, when he expects the first pilots of the Global Antimicrobial Resistance Innovation Fund on reimbursement models to incentivise the development of new classes of antibiotics to begin.

To which Nicola Blackwood Parliamentary Under-Secretary (Department of Health) replied:
The Global Antimicrobial Resistance (AMR) Innovation Fund is a £50 million investment over five years to tackle AMR, with the aim of attracting significant additional investment internationally to stimulate global research. It is not looking at reimbursement models to incentivise the development of new classes of antibiotics or planning to fund pilots at this stage. Domestically, the Department is working with the National Institute for Health and Care Excellence and the Association of the British Pharmaceutical Industry to develop a new reimbursement model for antimicrobials, and has secured broad agreement to principles that would permit a model to ‘de-link’ company revenues from sales. The aim of this work is to support good antimicrobial stewardship. Discussions with a number of leading pharmaceutical companies have highlighted challenges in evaluating antimicrobial medicines, and the Department is working closely with industry partners to address these.

To read more about this, please click here.

Kevin Hollinrake also asked the Secretary of State for Health when he expects the Global Antimicrobial Resistance Innovation Fund to be open to research applications for the repurposing of antibiotics.

To which Nicola Blackwood replied

The Government has committed £50 million towards setting up a Global Antimicrobial Resistance (AMR) Innovation Fund to increase global investment in AMR. The fund aims to leverage substantial new international investment in AMR research and development for new and repurposed antimicrobials and alternative medicines, rapid diagnostic tests, vaccines and other important technologies, interventions and therapies.

Professor Dame Sally Davies, the Chief Medical Officer for England and United Kingdom Government adviser, has appointed an expert advisory board to make recommendations on the scope and focus of the investment.

These discussions are ongoing.

To read more about this, please click here.

Tagged with

Published on 10. April 2017 in News UK